Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Stock analysts at William Blair dropped their Q2 2025 earnings per share estimates for Upstream Bio in a research note issued on Tuesday, May 6th. William Blair analyst M. Phipps now expects that the company will post earnings of ($0.59) per share for the quarter, down from their prior estimate of ($0.42). The consensus estimate for Upstream Bio's current full-year earnings is ($4.30) per share. William Blair also issued estimates for Upstream Bio's Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($2.61) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.35) EPS, FY2028 earnings at ($2.45) EPS and FY2029 earnings at ($2.62) EPS.
Upstream Bio Price Performance
UPB stock traded down $0.63 during mid-day trading on Thursday, hitting $8.87. 146,501 shares of the company were exchanged, compared to its average volume of 325,958. The firm has a fifty day simple moving average of $8.06 and a 200 day simple moving average of $13.31. Upstream Bio has a twelve month low of $5.14 and a twelve month high of $29.46.
Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The firm had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.71 million.
Hedge Funds Weigh In On Upstream Bio
A number of hedge funds have recently bought and sold shares of UPB. BNP Paribas Financial Markets acquired a new position in shares of Upstream Bio in the 4th quarter worth approximately $25,000. US Bancorp DE bought a new position in Upstream Bio during the fourth quarter worth $27,000. Legal & General Group Plc acquired a new position in Upstream Bio in the fourth quarter worth $28,000. Summit Investment Advisors Inc. bought a new stake in Upstream Bio during the fourth quarter valued at $30,000. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of Upstream Bio during the fourth quarter worth $47,000.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
